San Clemente-based heart device maker Cameron Health Inc. plans to use $107 million from a recent round of venture capital to complete a U.S. clinical trial, boost overseas sales and expand manufacturing here.
Cameron’s sole product is an implantable heart defibrillator.
The company now has raised nearly $200 million in financing, with the latest round led by Palo Alto’s Alloy Ventures and Delphi Ventures of Menlo Park.
It’s getting ready to start a 335-patient trial and intends to submit data to the Food and Drug Administration in early 2012, Chief Executive Kevin Hykes said.
“It’s the most rigorous type of trial as the patients, on average, are to be followed six months to a year,” Hykes said. The device “literally protects people from death.”
Cameron’s defibrillator is implanted under the skin and provides an electric shock to interrupt potentially fatal rhythms during heart attacks.
It differs from others because it operates without electric lead wires within a patient’s veins. Instead, it directly links to the heart, lessening the risk of fractures and scar tissue.
If Cameron submits trial data to regulators in early 2012, Hykes estimated that a decision could come down in “the back half of 2013.”
“We have a pretty good head start on anyone with anything remotely close to it, (so) we have some advantage in even a tough fund raising environment because it’s an interesting opportunity,” Hykes said.
The device maker now has no U.S. revenue. It expects full-year sales of $10 million to $12 million in Europe, where the device is approved.
Hykes is a former executive with Medtronic and Visiogen Inc., an Irvine eye device maker that’s now part of Abbott Laboratories of the Chicago area. He joined Cameron in early 2010.
The company “has sort of burst onto the scene—we’ve really come out of nine years of intense R&D effort, very much in stealth mode in Southern California,” Hykes said in an earlier interview.
When Cameron expands manufacturing, it will remain in San Clemente “for lots of reasons, not the least of which (is) the quality control aspect,” Hykes said. “The devices have to work or people die.”
Cameron is on the radar of big medical device makers, including Natick, Mass.-based Boston Scientific Corp., an investor that has the right to buy the company. Its name also has been linked to St. Jude Medical Inc. of St. Paul, Minn., and Minneapolis-based Medtronic Inc.
Cameron could seek to do an initial public offering or sell to another company if Boston Scientific, which made an undisclosed investment in the company in 2004, passes on its option to acquire it.
Cameron’s funding round is one of the largest seen here.
Fisker Automotive Inc., an Anaheim-based hybrid auto developer, raised $100 million earlier this month, bringing its total raised to $1 billion in investor and government financing.
Last year, Boston investment bank Leerink Swann LLC took the unusual step of highlighting Cameron as a company whose product could change the cardiac rhythm management industry and make it a potential buyout target.
Cameron’s design avoids problems with electrical lead wires, which have led to complications, regulatory recalls and bad publicity—something analysts have said blemished the implantable defibrillator sector’s growth and progress.
Cameron’s “unique, differentiated, disruptive technology” could have a major impact on the worldwide heart rhythm management market, which is worth more than $7 billion yearly, said Rick Wise, a Leerink analyst who hosted a conference call on the company.
Larger companies “may need to consider developing (or) gaining access to this technology as it becomes more real,” according to the invitation to the conference call.
Boston Scientific officials also have separately addressed Cameron.
During a 2010 conference, Ray Elliott, Boston Scientific’s chief executive, said there would be a role for an implantable defibrillator without leads “whether Cameron turns out to be the solution or somebody else.”
Boston Scientific plans “to have a play in that area,” Elliott said.
Cameron has planned for other scenarios if Boston Scientific chooses not to buy it, according to Hykes.
The company believes its devices could be used in some 40% of patients who need implantable defibrillators.
“That’s in the neighborhood of a $2 billion piece of the pie,” Hykes said.
Cameron’s funding history includes an initial round of $3 million in 2001 and later rounds of $31.2 million in 2006 and $51.5 million in 2008.
Versant Venture Management LLC, a Bay Area firm with a Newport Beach office, is one of Cameron’s investors. William Link, an Orange County-based Versant managing director and a Cameron board member, said the device maker’s performance “has exceeded our expectations.”